230 related articles for article (PubMed ID: 27926776)
1. Synuclein-γ in uterine serous carcinoma impacts survival: An NRG Oncology/Gynecologic Oncology Group study.
Winder AD; Maniar KP; Wei JJ; Liu D; Scholtens DM; Lurain JR; Schink JC; Buttin BM; Filiaci VL; Lankes HA; Ramirez NC; Park K; Singh M; Lieberman RW; Mannel RS; Powell MA; Backes FJ; Mathews CA; Pearl ML; Secord AA; Peace DJ; Mutch DG; Creasman WT; Kim JJ
Cancer; 2017 Apr; 123(7):1144-1155. PubMed ID: 27926776
[TBL] [Abstract][Full Text] [Related]
2. Synuclein-γ (SNCG) expression in ovarian cancer is associated with high-risk clinicopathologic disease.
Strohl A; Mori K; Akers S; Bshara W; Buttin B; Frederick PJ; Helenowski IB; Morrison CD; Odunsi K; Schink JC; Scholtens DM; Wei JJ; Kim JJ
J Ovarian Res; 2016 Nov; 9(1):75. PubMed ID: 27809878
[TBL] [Abstract][Full Text] [Related]
3. Synuclein-gamma (SNCG) may be a novel prognostic biomarker in uterine papillary serous carcinoma.
Morgan J; Hoekstra AV; Chapman-Davis E; Hardt JL; Kim JJ; Buttin BM
Gynecol Oncol; 2009 Aug; 114(2):293-8. PubMed ID: 19476987
[TBL] [Abstract][Full Text] [Related]
4. Neuronal protein synuclein gamma predicts poor clinical outcome in breast cancer.
Guo J; Shou C; Meng L; Jiang B; Dong B; Yao L; Xie Y; Zhang J; Chen Y; Budman DR; Shi YE
Int J Cancer; 2007 Sep; 121(6):1296-305. PubMed ID: 17534899
[TBL] [Abstract][Full Text] [Related]
5. Uterine carcinosarcoma and high-risk endometrial carcinomas: a clinicopathological comparison.
Zhang C; Hu W; Jia N; Li Q; Hua K; Tao X; Wang L; Feng W
Int J Gynecol Cancer; 2015 May; 25(4):629-36. PubMed ID: 25633654
[TBL] [Abstract][Full Text] [Related]
6. Uterine serous and grade 3 endometrioid carcinomas: is there a survival difference?
Boruta DM; Gehrig PA; Groben PA; Bae-Jump V; Boggess JF; Fowler WC; Van Le L
Cancer; 2004 Nov; 101(10):2214-21. PubMed ID: 15452833
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of synuclein-γ predicts lack of benefit from radiotherapy for breast cancer patients.
Min L; Zhang C; Ma R; Li X; Yuan H; Li Y; Chen R; Liu C; Guo J; Qu L; Shou C
BMC Cancer; 2016 Sep; 16(1):717. PubMed ID: 27595752
[TBL] [Abstract][Full Text] [Related]
8. Expression of neuronal protein synuclein gamma gene as a novel marker for breast cancer prognosis.
Wu K; Quan Z; Weng Z; Li F; Zhang Y; Yao X; Chen Y; Budman D; Goldberg ID; Shi YE
Breast Cancer Res Treat; 2007 Mar; 101(3):259-67. PubMed ID: 16821081
[TBL] [Abstract][Full Text] [Related]
9. Identification of γ-synuclein as a stage-specific marker in bladder cancer by immunohistochemistry.
Zhao J; Xing N
Med Sci Monit; 2014 Dec; 20():2550-5. PubMed ID: 25479371
[TBL] [Abstract][Full Text] [Related]
10. Human epidermal growth factor 2 (HER2) in early stage uterine serous carcinoma: A multi-institutional cohort study.
Erickson BK; Najjar O; Damast S; Blakaj A; Tymon-Rosario J; Shahi M; Santin A; Klein M; Dolan M; Cimino-Mathews A; Buza N; Ferriss JS; Stone RL; Khalifa M; Fader AN
Gynecol Oncol; 2020 Oct; 159(1):17-22. PubMed ID: 32709539
[TBL] [Abstract][Full Text] [Related]
11. Clinical significance of Her-2/neu overexpression in uterine serous carcinoma.
Díaz-Montes TP; Ji H; Smith Sehdev AE; Zahurak ML; Kurman RJ; Armstrong DK; Bristow RE
Gynecol Oncol; 2006 Jan; 100(1):139-44. PubMed ID: 16182348
[TBL] [Abstract][Full Text] [Related]
12. Trends in Survival of Patients With Uterine Serous Carcinoma From 1988 to 2011: A Population-Based Study.
Mahdi H; Han X; Moulton L; Vargas R
Int J Gynecol Cancer; 2017 Jul; 27(6):1155-1164. PubMed ID: 28562471
[TBL] [Abstract][Full Text] [Related]
13. Clinical predictors of long-term survival for stage IVB uterine papillary serous carcinoma confined to the abdomen.
Lee LJ; Demaria R; Berkowitz R; Matulonis U; Viswanathan AN
Gynecol Oncol; 2014 Jan; 132(1):65-9. PubMed ID: 24211401
[TBL] [Abstract][Full Text] [Related]
14. Impact of Chemotherapy and Radiotherapy on Management of Early Stage Clear Cell and Papillary Serous Carcinoma of the Uterus.
Hong JC; Foote J; Broadwater G; Gaillard S; Havrilesky LJ; Chino JP
Int J Gynecol Cancer; 2017 May; 27(4):720-729. PubMed ID: 28375927
[TBL] [Abstract][Full Text] [Related]
15. BRCA1 immunohistochemical staining as a prognostic indicator in uterine serous carcinoma.
Beirne JP; Quinn JE; Maxwell P; Kalloger SE; McAlpine J; Gilks CB; Harley IJ; McCluggage WG
Int J Gynecol Cancer; 2013 Jan; 23(1):113-8. PubMed ID: 23221734
[TBL] [Abstract][Full Text] [Related]
16. Expression of γ-Synuclein in Bladder Carcinoma: A Possible Marker for Prognosis.
Chen Z; Ji Z; Wang Q; Shi B; Shou C; Liu C; Fan H; Li H; Davidson KT; Wakefield MR; Ball TW; Fang Y
Anticancer Res; 2016 Mar; 36(3):951-6. PubMed ID: 26976983
[TBL] [Abstract][Full Text] [Related]
17. Racial differences in the overexpression of epidermal growth factor type II receptor (HER2/neu): a major prognostic indicator in uterine serous papillary cancer.
Santin AD; Bellone S; Siegel ER; Palmieri M; Thomas M; Cannon MJ; Kay HH; Roman JJ; Burnett A; Pecorelli S
Am J Obstet Gynecol; 2005 Mar; 192(3):813-8. PubMed ID: 15746676
[TBL] [Abstract][Full Text] [Related]
18. Impact of management on the prognosis of pure uterine papillary serous cancer - a Taiwanese Gynecologic Oncology Group (TGOG) study.
Huang CY; Tang YH; Chiang YC; Wang KL; Fu HC; Ke YM; Lau HY; Hsu KF; Wu CH; Cheng WF
Gynecol Oncol; 2014 May; 133(2):221-8. PubMed ID: 24556064
[TBL] [Abstract][Full Text] [Related]
19. Tumor suppressor gene, cell surface adhesion molecule, and multidrug resistance in Müllerian serous carcinomas: clinical divergence without immunophenotypic differences.
Soslow RA; Slomovitz BM; Saqi A; Baergen RN; Caputo TA
Gynecol Oncol; 2000 Dec; 79(3):430-7. PubMed ID: 11104615
[TBL] [Abstract][Full Text] [Related]
20. [Diagnosis, treatment and prognosis of uterine serous carcinoma].
Zhang F; Deng LS; Li B; Huang MN; Li XG; Zhang R; Wu LY
Zhonghua Fu Chan Ke Za Zhi; 2020 Dec; 55(12):848-856. PubMed ID: 33355760
[No Abstract] [Full Text] [Related]
[Next] [New Search]